参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Bone Cancer Version 1.2019-August 3,2018.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Womer RB,West DC,Krailo MD,et al.Randomized Controlled Trail of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma:A Report from the Children's Oncology Group.J Clin Oncol 2012, 30(33):4148-4154.
4.Yarchoan M,Hopkins A,Jaffee EM.Tumor Mutational Burden and Response Rate to PD-1 Inhibition.N Engl J Med 2017, 377:2500-2501.
5.Ailon T,Torabi R,Fisher CG,et al.Management of Locally Recurrent Chordoma of the Mobile Spine and Sacrum:A Systematic Review.Spine (Phila Pa 1976) 2016, 41 Suppl 20:S193-S198.
6.Kager L,Zoubek A,Potschger U,et al.Primary metastatic osteosarcoma:presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.J Clin Oncol 2003, 21:2011-2018.
7.Le DT,Durham JN,Smith KN,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science 2017, 357:409-413.
8.Grevener K,Haveman LM,Ranft A,et al.Management and Outcome of Ewing Sarcoma of the Head and Neck.Pediatr Blood Cancer 2016, 63:604-610.
9.Brown HK,Schiavone K,Gouin F,et al.Biology of Bone Sarcomas and New Therapeutic Developments.Calcif Tissue Int 2018, 102:174-195.
10.Andreou D,Gilg MM,Gosheger G,et al.Metastatic Potential of Grade I Chondrosarcoma of Bone:Results of a Multi-institutional Study.Ann Surg Oncol 2016, 23:120-125.
11.Bertrand TE,Cruz A,Binitie O,et al.Do Surgical Margins Affect Local Recurrence and Survival in Extremity,Nonmetastatic,High-grade Osteosarcoma? Clin Orthop Relat Res 2016, 474:677-683.
12.Li X,Shao C,Shi Y, et al.Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.J Hematol Oncol 2018, 11:31.(https://www.daowen.com)
13.Gonzalez Del Pino J,Lozano Calderon SA,Chebib I, et al.Intralesional Versus Wide Resection of Low-Grade Chondrosarcomas of the Hand.J Hand Surg Am 2016, 41:541-549 e545.
14.Palmerini E,Jones RL,Marchesi E,et al.Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.BMC Cancer 2016, 16:280.
15.Schneiderman BA,Kliethermes SA,Nystrom LM.Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location:A Survival Analysis of the SEER Database.Clin Orthop Relat Res 2017, 475:799-805.
16.Pennicooke B,Laufer I,Sahgal A,et al.Safety and Local Control of Radiation Therapy for Chordoma of the Spine and Sacrum:A Systematic Review.Spine (Phila Pa 1976) 2016, 41 Suppl 20:S186-S192.
17.Ferrari S,Luksch R,Hall KS,et al.Post-relapse survival in patients with Ewing sarcoma.Pediatr Blood Cancer 2015, 62:994-999.
18.McDonald MW,Linton OR,Moore MG,et al.Influence of Residual Tumor Volume and Radiation Dose Coverage in Outcomes for Clival Chordoma.Int J Radiat Oncol Biol Phys 2016, 95:304-311.
19.Sukari A,Nagasaka M,Al-Hadidi A, et al.Cancer Immunology and Immunotherapy.Anticancer Res 2016, 36:5593-5606.
20.Chalmers ZR,Connelly CF,Fabrizio D,et al.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med 2017, 9:34.
21.Imai R,Kamada T,Araki N,et al.Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma:An Analysis of 188 Cases.Int J Radiat Oncol Biol Phys 2016, 95:322-327.
22.Casey DL,Wexler LH,Meyers PA,et al.Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.Pediatr Blood Cancer 2015, 62:445-449.
23.Bedetti B,Wiebe K,Ranft A,et al.Local control in Ewing sarcoma of the chest wall:results of the EURO-EWING 99 trial.Ann Surg Oncol 2015, 22:2853-2859.
24.Ferrari S,Luksch R,Hall KS,et al.Post-relapse survival in patients with Ewing sarcoma.Pediatr Blood Cancer 2015, 62:994-999.